8TH ANNUAL
FOCUS ON
NEUROENDOCRINE TUMORS

A PATIENT & CAREGIVER PROGRAM

Friday, March 8, 2019
8 am – 2:30 pm

REGISTER ONLINE AT
PennMedicine.org/Abramson/NETs

Attend in Person or View Livestream

OPEN TO THE PUBLIC
Law Auditorium // Jordan Medical Education Center // Perelman Center for Advanced Medicine
3400 Civic Center Boulevard // Philadelphia, PA 19104
WHO SHOULD ATTEND:
Newly diagnosed, currently in treatment or long-term survivor of:

- Gastrointestinal Tract NETs including: Pancreatic NETs (hereditary or sporadic)
  - Zollinger-Ellison syndrome (gastrinomas)
  - Insulinomas
  - Alimentary tract NETs (foregut, midgut or hindgut)
  - Functional (carcinoid syndrome)
  - Non-functional
  - Bronchial, Thymic and Carcinoid in other locations
- Pheochromocytomas and Paragangliomas including hereditary and sporadic forms
- Hereditary Syndromes associated with Neuroendocrine Tumors

If you are a family member or caregiver

DATE
Friday, March 8, 2019

TIME
8 am – 2:30 pm

LOCATION
Law Auditorium
Jordan Medical Education Center
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104

FREE Parking, Breakfast & Lunch!

FOLLOW US
PennCancer
@PennCancer
#PhillyNETS

REGISTRATION
To register or for more information, call 800.789.PENN (7366) or visit PennMedicine.org/Abramson/NETS.

Parking will be validated — Parking information can be found at PennMedicine.org.

$25 suggested donation (non-tax deductible) to support the Focus On Neuroendocrine Tumors Conference. Credit cards accepted with on-line registration. Cash, check, money order or credit card accepted the day of the conference.
AGENDA

8:00 am  Check-In  
Continental Breakfast, Visit Exhibits and Experts

8:40 am  Welcome Opening Remarks  
Debbie L. Cohen, MD, Conference Co-Chair  
Joseph R. Carver, MD, Chief of Staff, Abramson Cancer Center

8:45 am  News from the Abramson Cancer Center  
Andrew Bellet, Major Gifts Officer, Abramson Cancer Center

MORNING SESSION

9:15 am  Management of NETs – Overview  
David C. Metz, MD, Gastroenterology  
Debbie L. Cohen, MD, Nephrology

9:35 am  Penn NET Center – Overview of Clinical & Basic Science Research  
Bryson W. Katona, MD, PhD, Gastroenterology  
Heather Wachtel MD, Endocrine & Oncologic Surgery

9:55 am  Use of PRRT for NETS  
Daniel A. Pryma, MD, Radiology, Nuclear Medicine

10:15 am  Genetics Update  
Anna C. Raper, MS, Genetics

10:35 am  Break

10:45 am  Systemic therapy for metastatic NETs  
Jennifer Eads, MD, Hematology Oncology

11:05 am  KEYNOTE SPEAKER  
The role of Endocrinologist in the Management of NETs  
Lauren M. Fishbein, MD, PhD, MTR, Endocrinology, Metabolism, Diabetes

11:35 am  Lunch

CONFERENCE CO-CHAIRS

David C. Metz, MD, Professor of Medicine, Gastroenterology, Co-Director, Neuroendocrine Tumor Center

Debbie L. Cohen, MD, Associate Professor of Medicine, Director of Clinical Hypertension Programs, Co-director of Neuroendocrine Tumor Program
AFTERNOON SESSION

12:20 pm  Multidisciplinary Team Approach for Managing NETs

MODERATORS
David C. Metz, MD & Debbie L. Cohen, MD

PANEL MEMBERS
Lauren M. Fishbein, MD, PhD, MTR, Endocrinology, Metabolism, Diabetes
Maria L. Bonanni, NP, Genetics
Diann E. Boyd, BSN, RN, OCN, Oncology Nurse Navigator
Jason Brant, MD, Otorhinolaryngology
Joseph R. Carver, MD, Cardiology
Keith A. Cengel, MD, PhD, Radiation Oncology
Nevena Damjanov, MD, Medical Oncology
Jennifer Eads, MD, Hematology Oncology
Anna Jung, PharmD, BCPS, GI Pharmacist
Julia N. Kharlip, MD, Endocrinology
John C. Kucharczuk, MD, Thoracic Surgery
Daniel A. Pryma, MD, Radiology, Nuclear Medicine
Robert E. Roses, MD, Endocrine & Oncologic Surgery
Michael C. Soulen, MD, Interventional Radiology
Ursina R. Teitelbaum, MD, Medical Oncology/Palliative Care
Heather Wachtel, MD, Endocrine & Oncologic Surgery

1:50 pm  Patient Power – It Takes Guts

MODERATORS
Neal Niznan, MSW, LCSW & Bonnie J. Bennett, BSN, RN

2:30 pm  Conference Closing

EXHIBIT HALL

Visit our experts in Survivorship and Integrative Therapies

• Integrative Therapies
• Surgery Nurse
• Coping with Emotions
• Giving Back
• Good Shepherd Penn Partners – Penn Therapy and Fitness Optional
• Managing GI Symptoms
• Managing Symptoms – Liver Directed Therapy
• Managing Symptoms – Chemotherapy
• Nutrition
• Nurse Navigation
• Palliative Care
The Focus on Neuroendocrine Tumors Conference is being held in collaboration with the Penn Medicine Development Office. Attendees will receive communication from the PENN Medicine Development Office regarding their research and programs. Participation in this conference is optional and patient privacy has been maintained. If you would prefer not to receive development materials, we will make reasonable efforts to honor such a request. Please send a written request with your name, and address to Tricia Bruning, Abramson Cancer Center Development Office, 3535 Market Street, Suite 750, Philadelphia, PA 19104.

KEYNOTE SPEAKER
Lauren M. Fishbein, MD, PhD, MTR

Lauren M. Fishbein, MD, PhD, MTR is an Assistant Professor in Medicine at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes with a secondary appointment in the Division of Biomedical Informatics and Personalized Medicine. She received her bachelor’s degree in Biochemistry from Vassar College and earned her MD, PhD degree from the University of Florida with a PhD in Molecular Genetics. She completed her Internal Medicine Residency at Harvard’s Beth Israel Deaconess Medical Center in Boston and her Endocrinology Fellowship at the University of Pennsylvania where she also completed a Master’s in Translational Research. Her research and clinical interests are in neuroendocrine tumor genetics with a special focus on pheochromocytomas and paragangliomas. Dr. Fishbein has a strong interest in personalized medicine including understanding the impacts and implications of germline predisposition genetics, as well as understanding tumor development and transformation to aggressive and metastatic disease. Among her contributions to the field, she, along with her collaborators, was the first to report the association between somatic ATRX mutations and aggressive pheochromocytoma, and she was the data coordinator for The Cancer Genome Atlas (TCGA) integrative genomics study on pheochromocytoma and paraganglioma. She has served and continues to serve on committees for the Endocrine Society, and she is currently a member of the Guidelines and Publications Committee for the North American Neuroendocrine Tumor Society.

ABOUT Abramson Cancer Center
PennMedicine.org/Abramson

At the Abramson Cancer Center our mission is to reduce the burden of cancer throughout our region, the nation and the world through the development of an integrated program of laboratory, clinical and population based research. The Abramson Cancer Center has been continuously designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973. The Abramson Cancer Center was rated “EXCEPTIONAL” by the NCI at our last competitive review — the highest possible rating a Center can receive.